{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-205107","form_type":"8-K","ticker":"APVO","cik":"0001671584","company_name":"Aptevo Therapeutics Inc.","filed_at":"2025-09-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.602866+00:00","generated_at":"2026-05-17T06:30:24.062070+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Aptevo reports 100% remission rate in Cohort 3 of Phase 1b/2 RAINIER trial for mipletamig in AML","bullets":["100% remission rate (CR/CRi) in Cohort 3 with mipletamig + venetoclax + azacitidine for newly diagnosed AML unfit for intensive chemo.","No dose-limiting toxicities or cytokine release syndrome observed across all RAINIER cohorts; safety profile clean.","40% of treated patients achieved minimal residual disease (MRD)-negative status, a marker associated with improved outcomes.","Cohort 4 now enrolling at next dose level; data expected at major medical conference in Q4 2025.","Frontline AML market is multibillion-dollar; mipletamig could redefine standard of care if later-stage data confirm."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-205107","json":"https://secwatch.observer/filing/0001193125-25-205107.json","markdown":"https://secwatch.observer/filing/0001193125-25-205107.md","text":"https://secwatch.observer/filing/0001193125-25-205107.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671584/000119312525205107/0001193125-25-205107-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671584/000119312525205107/apvo-20250916.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:30:24.062070+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}